Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding

Grigoris I. Leontiadis, Virender K. Sharma, Colin Howden

Research output: Contribution to journalReview article

122 Citations (Scopus)

Abstract

Objectives: To review randomised controlled trials of treatment with a proton pump inhibitor in patients with ulcer bleeding and to determine the impact on mortality, rebleeding, and surgical intervention. Design: Systematic review and meta-analysis. Data sources: Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies. Review methods: Included randomised controlled trials that compared proton pump inhibitor with placebo or H2 receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus. Results We included 21 randomised controlled trials comprising 2915 patients. Proton pump inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95% confidence interval 0.79 to 1.57; number needed to treat (NNT) incalculable) but reduced rebleeding (0.46, 0.33 to 0.64; NNT 12) and surgery (0.59,0.46 to 0.76; NNT 20). Results were similar when the meta-analysis was restricted to the 10 trials with the highest methodological quality: 0.96, 0.46 to 2.01, for mortality; 0.41, 0.25 to 0.68, NNT 10, for rebleeding; 0.62, 0.46 to 0.83, NNT 25, for surgery. Conclusions: Treatment with a proton pump inhibitor reduces the risk of rebleeding and the requirement for surgery after ulcer bleeding but has no benefit on overall mortality.

Original languageEnglish (US)
Pages (from-to)568-570
Number of pages3
JournalBritish Medical Journal
Volume330
Issue number7491
DOIs
StatePublished - Mar 12 2005

Fingerprint

Numbers Needed To Treat
Proton Pump Inhibitors
Peptic Ulcer
Meta-Analysis
Hemorrhage
Mortality
Ulcer
Randomized Controlled Trials
Therapeutics
Histamine H2 Receptors
Information Storage and Retrieval
Odds Ratio
Placebos
Confidence Intervals
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. / Leontiadis, Grigoris I.; Sharma, Virender K.; Howden, Colin.

In: British Medical Journal, Vol. 330, No. 7491, 12.03.2005, p. 568-570.

Research output: Contribution to journalReview article

Leontiadis, Grigoris I. ; Sharma, Virender K. ; Howden, Colin. / Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. In: British Medical Journal. 2005 ; Vol. 330, No. 7491. pp. 568-570.
@article{e4ae1d0611ba44a2be7aaf0cc6c3daa9,
title = "Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding",
abstract = "Objectives: To review randomised controlled trials of treatment with a proton pump inhibitor in patients with ulcer bleeding and to determine the impact on mortality, rebleeding, and surgical intervention. Design: Systematic review and meta-analysis. Data sources: Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies. Review methods: Included randomised controlled trials that compared proton pump inhibitor with placebo or H2 receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus. Results We included 21 randomised controlled trials comprising 2915 patients. Proton pump inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95{\%} confidence interval 0.79 to 1.57; number needed to treat (NNT) incalculable) but reduced rebleeding (0.46, 0.33 to 0.64; NNT 12) and surgery (0.59,0.46 to 0.76; NNT 20). Results were similar when the meta-analysis was restricted to the 10 trials with the highest methodological quality: 0.96, 0.46 to 2.01, for mortality; 0.41, 0.25 to 0.68, NNT 10, for rebleeding; 0.62, 0.46 to 0.83, NNT 25, for surgery. Conclusions: Treatment with a proton pump inhibitor reduces the risk of rebleeding and the requirement for surgery after ulcer bleeding but has no benefit on overall mortality.",
author = "Leontiadis, {Grigoris I.} and Sharma, {Virender K.} and Colin Howden",
year = "2005",
month = "3",
day = "12",
doi = "10.1136/bmj.38356.641134.8F",
language = "English (US)",
volume = "330",
pages = "568--570",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "7491",

}

TY - JOUR

T1 - Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding

AU - Leontiadis, Grigoris I.

AU - Sharma, Virender K.

AU - Howden, Colin

PY - 2005/3/12

Y1 - 2005/3/12

N2 - Objectives: To review randomised controlled trials of treatment with a proton pump inhibitor in patients with ulcer bleeding and to determine the impact on mortality, rebleeding, and surgical intervention. Design: Systematic review and meta-analysis. Data sources: Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies. Review methods: Included randomised controlled trials that compared proton pump inhibitor with placebo or H2 receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus. Results We included 21 randomised controlled trials comprising 2915 patients. Proton pump inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95% confidence interval 0.79 to 1.57; number needed to treat (NNT) incalculable) but reduced rebleeding (0.46, 0.33 to 0.64; NNT 12) and surgery (0.59,0.46 to 0.76; NNT 20). Results were similar when the meta-analysis was restricted to the 10 trials with the highest methodological quality: 0.96, 0.46 to 2.01, for mortality; 0.41, 0.25 to 0.68, NNT 10, for rebleeding; 0.62, 0.46 to 0.83, NNT 25, for surgery. Conclusions: Treatment with a proton pump inhibitor reduces the risk of rebleeding and the requirement for surgery after ulcer bleeding but has no benefit on overall mortality.

AB - Objectives: To review randomised controlled trials of treatment with a proton pump inhibitor in patients with ulcer bleeding and to determine the impact on mortality, rebleeding, and surgical intervention. Design: Systematic review and meta-analysis. Data sources: Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies. Review methods: Included randomised controlled trials that compared proton pump inhibitor with placebo or H2 receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus. Results We included 21 randomised controlled trials comprising 2915 patients. Proton pump inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95% confidence interval 0.79 to 1.57; number needed to treat (NNT) incalculable) but reduced rebleeding (0.46, 0.33 to 0.64; NNT 12) and surgery (0.59,0.46 to 0.76; NNT 20). Results were similar when the meta-analysis was restricted to the 10 trials with the highest methodological quality: 0.96, 0.46 to 2.01, for mortality; 0.41, 0.25 to 0.68, NNT 10, for rebleeding; 0.62, 0.46 to 0.83, NNT 25, for surgery. Conclusions: Treatment with a proton pump inhibitor reduces the risk of rebleeding and the requirement for surgery after ulcer bleeding but has no benefit on overall mortality.

UR - http://www.scopus.com/inward/record.url?scp=15044361087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044361087&partnerID=8YFLogxK

U2 - 10.1136/bmj.38356.641134.8F

DO - 10.1136/bmj.38356.641134.8F

M3 - Review article

VL - 330

SP - 568

EP - 570

JO - The BMJ

JF - The BMJ

SN - 0959-8146

IS - 7491

ER -